Chronic graft-versus-host disease

Current Opinion in Oncology

Volumn 18, Issue 2, 2006, Pages 126-131

  Cutler, Corey ^a,b   Antin, Joseph H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Allogeneic stem cell transplantation; Chronic graft versus host disease; Graft versus leukemia effect

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYCHLOROQUINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THALIDOMIDE;

ABSENCE OF SIDE EFFECTS; ALLOGENEIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE ACTIVATION; BLOOD TOXICITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG PULSE THERAPY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; RELAPSE; REVIEW; RISK BENEFIT ANALYSIS; STAGING; T LYMPHOCYTE ACTIVATION;

CHRONIC DISEASE; CLINICAL TRIALS; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HUMANS;

EID: 33646710816     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000208784.07195.84     Document Type: Review

References (56)

1. Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19:3685-3691.
2. Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood 2005; 105:4200-4206. An excellent and comprehensive review on novel approaches for prevention and treatment of chronic GVHD.
3. Weisdorf DJ. Chronic graft-versus-host disease: where is promise for the future? Leukemia 2005; 19:1532-1535. A comprehensive review on current and novel methods of treating and preventing chronic GVHD.
4. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100:406-414.
5. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341:14-21.
6. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98:3192-3204.
7. Pavletic SZ, Carter SL, Kernan NA, et al. Influence of T cell depletion on chronic graft-versus-host disease: results of a multi-center randomized trial in unrelated marrow donor transplantation. Blood 2005; 106:3308-3313. [Epub ahead of print] Important randomized clinical trial demonstrating a reduction in the incidence of acute GVHD with T-cell depletion, but no effects on the incidence of chronic GVHD, relapse rate, or long-term survival after transplantation.
8. Guglielmi C, Arcese W, Dazzi F, et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100:397-405.
9. Porter DL, Collins RH Jr, Shpilberg O, et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant 1999; 5:253-261.
10. Porter DL, Collins RH Jr, Hardy C, et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95:1214-1221.
11. Falkenburg JH, van de Corput L, Marijt EW, Willemze R. Minor histocompatibility antigens in human stem cell transplantation. Exp Hematol 2003; 31:743-751.
12. Miklos DB, Kim HT, Zorn E, et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004; 103:353-359.
13. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005; 105:2973-2978. A study correlating the presence of an anti-H-Y antibody response with the presence of chronic GVHD. In this series, the presence of any antibody against an H-Y antigen protected against malignant disease relapse.
14. Zorn E, Miklos DB, Floyd BH, et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med 2004; 199:1133-1142.
15. Cai J, Lee J, Jankowska-Gan E, et al. Minor H antigen HA-1-specific regulator and effector CD8+ T cells, and HA-1 microchimerism, in allograft tolerance. J Exp Med 2004; 199:1017-1023.
16. Parkman R. Graft-versus-host disease: an alternative hypothesis. Immunol Today 1989; 10:362-364.
17. Tivol E, Komorowski R, Drobyski WR. Emergent autoimmunity in graft-versus-host disease. Blood 2005; 105:4885-4891. An animal model of chronic GVHD used to dissect the role of autoimmunity compared with alloimmunity as a mechanism of chronic GVHD. The authors show that self-tolerance is lost in chronic GVHD, and donor T cells acquire the ability to recognize both self and recipient antigens in a donor antigen-presenting cell-dependent manner.
18. Cutler C, Mikos D, Lee S, et al. Rituxan for steroid-refractory chronic GVHD [abstract]. Biol Blood Marrow Transplant 2005; 11s1:10. A preliminary study on the largest group of patients treated with rituximab for steroid-refractory chronic GVHD. Responses were noted primarily in patients with cutaneous and rheumatologic manifestations of chronic GVHD.
19. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003; 9:505-511.
20. Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 21:2747-2753.
21. Sorror ML, Maris MB, Sandmaier BM, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23:3819-3829.
22. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69:204-217.
23. Lee S, Cook EF, Soiffer R, Antin JH. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8:444-452.
24. Akpek G, Lee SJ, Flowers ME, et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood 2003; 102:802-809.
25. Kansu E, Gooley T, Flowers ME, et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood 2001; 98:3868-3870.
26. Mengarelli A, Iori AP, Romano A, et al. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Haematologica 2003; 88:315-323.
27. Bacigalupo A, Maiolino A, van Lint MT, et al. Cyclosporin A and chronic graft versus host disease. Bone Marrow Transplant 1990; 6:341-344.
28. Lonnqvist B, Aschan J, Ljungman P, Ringden O. Long-term cyclosporin therapy may decrease the risk of chronic graft-versus-host disease. Br J Haematol 1990; 74:547-548.
29. Ruutu T, Volin L, Elonen E. Low incidence of severe acute and chronic graft-versus-host disease as a result of prolonged cyclosporine prophylaxis and early aggressive treatment with corticosteroids. Transplant Proc 1988; 20:491-493.
30. Koc S, Leisenring W, Flowers ME, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002; 100:48-51.
31. Arora M, Wagner JE, Davies SM, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001; 7:265-273.
32. Koc S, Leisenring W, Flowers ME, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000; 96:3995-3996.
33. Lopez F, Parker P, Nademanee A, et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11:307-313. Large retrospective experience using mycophenolate mofetil as therapy for denovo or refractory chronic GVHD, with responses noted in almost all patients.
34. Krejci M, Doubek M, Buchler T, et al. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 2005; 84:681-685. [Epub ahead of print] Small study demonstrating the effectiveness of mycophenolate mofetil in chronic GVHD.
35. Kim JG, Sohn SK, Kim DH, et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 2004; 73:56-61.
36. Busca A, Locatelli F, Marmont F, et al. Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease. Haematologica 2003; 88:837-839.
37. Baudard M, Vincent A, Moreau P, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 2002; 30:287-295.
38. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant 1999; 24:517-520.
39. Johnston LJ, Brown J, Shizuru JA, et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11:47-55. First study detailing the effectiveness and toxicity of sirolimus as therapy for steroid-refractory chronic GVHD. Renal toxicity was substantial.
40. Couriel DR, Saliba R, Escalon MP, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 2005; 130:409-417. Large prospective study of sirolimus as therapy for steroid-refractory chronic GVHD also demonstrating a substantial response rate.
41. Antin JH, Kim HT, Cutler C, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003; 102:1601-1605.
42. Cutler C, Kim HT, Hochberg E, et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004; 10:328-336.
43. Kulkarni S, Powles R, Sirohi B, et al. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant 2003; 32:165-170.
44. Browne PV, Weisdorf DJ, Defor T, et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant 2000; 26:865-869.
45. Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86:3604-3609.
46. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992; 326:1055-1058.
47. Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000; 133:275-279.
48. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004; 104:2603-2606. A small series of patients treated with rituximab. Pathologic correlates of disease response are presented.
49. Mayer J, Krejci M, Doubek M, et al. Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease. Bone Marrow Transplant 2005; 35:699-705. A small series of patients with chronic GVHD treated with a novel approach.
50. Gilman AL, Chan KW, Mogul A, et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6:327-334.
51. Akpek G, Lee SM, Anders V, Vogelsang GB. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001; 7:495-502.
52. Gorgun G, Miller KB, Foss FM. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 2002; 100:941-947.
53. Foss FM, Gorgun G, Miller KB. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transplant 2002; 29:719-725.
54. Foss FM, DiVenuti GM, Chin K, et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant 2005; 35:1187-1193. A prospective study of ECP in chronic GVHD demonstrates a significant steroid-sparing effect. In addition, prognostic factors that predict response are presented.
55. Seaton ED, Szydlo RM, Kanfer E, et al. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood 2003; 102:1217-1223.
56. Apisarnthanarax N, Donato M, Korbling M, et al. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant 2003; 31:459-465.